These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 33321510)

  • 1. High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison?
    Türk M; Yılmaz İ
    Int Arch Allergy Immunol; 2021; 182(5):461-462. PubMed ID: 33321510
    [No Abstract]   [Full Text] [Related]  

  • 2. Ligelizumab for chronic spontaneous urticaria.
    Sabroe RA
    Br J Dermatol; 2020 Nov; 183(5):829-830. PubMed ID: 32002982
    [No Abstract]   [Full Text] [Related]  

  • 3. A case of chronic spontaneous urticaria unresponsive to ligelizumab successfully treated with omalizumab.
    Russo F; Cortonesi G; Lazzeri L; Taddeucci P; Rubegni P
    Dermatol Ther; 2022 Nov; 35(11):e15859. PubMed ID: 36164841
    [No Abstract]   [Full Text] [Related]  

  • 4. Ligelizumab Is Superior to Omalizumab for Chronic Spontaneous Urticaria.
    Muntyanu A; Ouchene L; Ben-Shoshan M; Netchiporouk E
    J Cutan Med Surg; 2020; 24(2):201-202. PubMed ID: 32208012
    [No Abstract]   [Full Text] [Related]  

  • 5. Ligelizumab for Chronic Spontaneous Urticaria.
    Maurer M; Giménez-Arnau AM; Sussman G; Metz M; Baker DR; Bauer A; Bernstein JA; Brehler R; Chu CY; Chung WH; Danilycheva I; Grattan C; Hébert J; Katelaris C; Makris M; Meshkova R; Savic S; Sinclair R; Sitz K; Staubach P; Wedi B; Löffler J; Barve A; Kobayashi K; Hua E; Severin T; Janocha R
    N Engl J Med; 2019 Oct; 381(14):1321-1332. PubMed ID: 31577874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria.
    Moussa S; Netchiporouk E
    Lancet; 2024 Jan; 403(10422):118-119. PubMed ID: 38008108
    [No Abstract]   [Full Text] [Related]  

  • 7. Ligelizumab for the treatment of chronic spontaneous urticaria.
    Wedi B
    Expert Opin Biol Ther; 2020 Aug; 20(8):853-861. PubMed ID: 32380864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligelizumab for Chronic Spontaneous Urticaria.
    Weinberger M
    N Engl J Med; 2020 Feb; 382(6):579. PubMed ID: 32023385
    [No Abstract]   [Full Text] [Related]  

  • 9. Ligelizumab for Chronic Spontaneous Urticaria.
    Cohen JM
    N Engl J Med; 2020 Feb; 382(6):579. PubMed ID: 32023384
    [No Abstract]   [Full Text] [Related]  

  • 10. Ligelizumab for Chronic Spontaneous Urticaria. Reply.
    Center DM
    N Engl J Med; 2020 Feb; 382(6):580. PubMed ID: 32023387
    [No Abstract]   [Full Text] [Related]  

  • 11. Ligelizumab for Chronic Spontaneous Urticaria. Reply.
    Maurer M; Giménez-Arnau AM; Metz M
    N Engl J Med; 2020 Feb; 382(6):579-580. PubMed ID: 32023386
    [No Abstract]   [Full Text] [Related]  

  • 12. IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms.
    Kuo BS; Li CH; Chen JB; Shiung YY; Chu CY; Lee CH; Liu YJ; Kuo JH; Hsu C; Su HW; Li YF; Lai A; Ho YF; Cheng YN; Huang HX; Lung MC; Wu MS; Yang FH; Lin CH; Tseng W; Yang J; Lin CY; Tsai PH; Chang HK; Wang YJ; Chen T; Lynn S; Liao MJ; Wang CY
    J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35912861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful ligelizumab treatment of severe refractory solar urticaria.
    Hershkovitz Y; Khanimov I; Rubin L; Dranitzki Z; Talmon A; Ribak Y; Shamriz O; Levi A; Tal Y
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2576-2577. PubMed ID: 36796509
    [No Abstract]   [Full Text] [Related]  

  • 14. Using National Registries to Identify Targeted Therapies for Refractory Urticaria.
    Khan S; Michaelis LJ; Dawson TC; Thusby-Pelham A; Pur Özyiğit L; Krishna MT; Erlewyn-Lajeunesse M
    Int Arch Allergy Immunol; 2021; 182(5):459-460. PubMed ID: 33690233
    [No Abstract]   [Full Text] [Related]  

  • 15. Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study.
    Maurer M; Giménez-Arnau A; Bernstein JA; Chu CY; Danilycheva I; Hide M; Makris M; Metz M; Savic S; Sitz K; Soong W; Staubach P; Sussman G; Barve A; Burciu A; Hua E; Janocha R; Severin T
    Allergy; 2022 Jul; 77(7):2175-2184. PubMed ID: 34773261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab re-treatment rates in chronic spontaneous urticaria.
    Khan S; Sholtysek S
    Eur Ann Allergy Clin Immunol; 2020 May; 52(4):187-189. PubMed ID: 32378397
    [No Abstract]   [Full Text] [Related]  

  • 17. High-dose omalizumab use in patients with chronic spontaneous urticaria.
    Alizadeh Aghdam M; van den Broek F; Rijken F; Knulst AC; Röckmann H
    J Allergy Clin Immunol Pract; 2020 Apr; 8(4):1426-1427.e1. PubMed ID: 31678293
    [No Abstract]   [Full Text] [Related]  

  • 18. A very low number of circulating basophils is predictive of a poor response to omalizumab in chronic spontaneous urticaria.
    Rijavec M; Košnik M; Koren A; Kopač P; Šelb J; Vantur R; Kogovšek Ž; Bizjak M; Bajrović N; Zidarn M; Korošec P
    Allergy; 2021 Apr; 76(4):1254-1257. PubMed ID: 32876979
    [No Abstract]   [Full Text] [Related]  

  • 19. Biologics for the Use in Chronic Spontaneous Urticaria: When and Which.
    Maurer M; Khan DA; Elieh Ali Komi D; Kaplan AP
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1067-1078. PubMed ID: 33685605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical predictive factors of unresponsiveness to omalizumab in patients with chronic spontaneous urticaria.
    Castagna J; Bernard L; Hacard F; Delcroix F; Darrigade AS; Nicolas JF; Decullier E; Nosbaum A; Bérard F
    Br J Dermatol; 2020 Dec; 183(6):1124-1126. PubMed ID: 32531805
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.